WASHINGTON, Nov 17 (Reuters) - Patients, doctors and the company that makes a prostate cancer vaccine all urged U.S. Medicare advisers on Wednesday to support their pleas to have federal insurance pay for Dendreon Corp's therapy regardless of its hefty price tag.